Astute Medical Logo
Innovative biomarkers.  Smarter healthcare.

Astute Medical Completes $13 Million Financing with Existing Stockholders

SAN DIEGO, CALIFORNIA - March 8, 2011 - Astute Medical, Inc. today announced the completion of a $13 million financing, which represents an extension of the Series B financing completed by the Company in May 2010. The transaction involved the sale of additional Series B shares to certain existing Series B stockholders including, but not limited to, Domain AssociatesDelphi VenturesDe Novo Ventures and Johnson & Johnson Development Corporation. The Company intends to use the proceeds to advance and expand its research, development and validation of biomarker-based laboratory tests.

About Astute Medical, Inc.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community and hospital acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please visit

Astute Medical, Inc.
Todd Myers
Chief Financial Officer
(858) 882-0497

©2019 Astute Medical, Inc. Astute Medical®, the AM logo, Astute140®NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see PN 0276 Rev A 2014/06/17